Bofanglutide
Sources
registry, as of 2025-11-25Stale
https://clinicaltrials.gov/study/NCT06728124
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 630. Conditions Obesity/Overweight. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.
ClinicalTrials.gov NCT06728124 protocol and results modules
registry, as of 2026-03-11Stale
https://clinicaltrials.gov/study/NCT07292441
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss. Overall status RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 500. Conditions Overweight or Obesity. This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on b
ClinicalTrials.gov NCT07292441 protocol and results modules
registry, as of 2025-11-25Stale
https://clinicaltrials.gov/study/NCT07150975
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects. Overall status RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 420. Conditions Obesity/Overweight in Adult. This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this
ClinicalTrials.gov NCT07150975 protocol and results modules
registry, as of 2026-03-27Stale
https://clinicaltrials.gov/study/NCT07493057
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 140. Conditions Obstructive Sleep Apnea (OSA). This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive air
ClinicalTrials.gov NCT07493057 protocol and results modules
registry, as of 2026-04-03Stale
https://clinicaltrials.gov/study/NCT07501832
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 140. Conditions Obstructive Sleep Apnea (OSA). The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of GZR18 injection in Chinese adult obese patients with moderate-to-severe obstructive sleep apnea (OSA) who are currently using p
ClinicalTrials.gov NCT07501832 protocol and results modules
registry, as of 2025-10-01Stale
https://clinicaltrials.gov/study/NCT06256562
A Study of GZR18 Injection in Obese/Overweight Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 340. Conditions Obesity; Overweight. This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.
ClinicalTrials.gov NCT06256562 protocol and results modules
registry, as of 2026-07-16Stale
https://clinicaltrials.gov/study/NCT06737042
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 326. Conditions Obesity and Overweight. This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-
ClinicalTrials.gov NCT06737042 protocol and results modules
registry, as of 2024-02-23Stale
https://clinicaltrials.gov/study/NCT06256536
A Study of GZR18 Injection in Chinese Obese/Overweight Patients. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 60. Conditions Obesity; Overweight. The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight patients. This study is divided into Part A and Part B, w
ClinicalTrials.gov NCT06256536 protocol and results modules
publication, as of 2026-07-10Stale
https://pubmed.ncbi.nlm.nih.gov/41760612/
overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Bofanglutide is a novel biweekly (once every two weeks; Q2W) glucagon-like peptide-1 receptor agonist. We evaluated the efficacy and safety of bofanglutide in Chinese adults with overweight or obesity in a random
PMID 41760612